Cidara Therapeutics Inc (CDTX)
19.30
+1.85
(+10.60%)
USD |
NASDAQ |
Nov 22, 15:25
Cidara Therapeutics Net Income (Quarterly): -15.98M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -15.98M |
| June 30, 2024 | -91.21M |
| March 31, 2024 | -10.33M |
| December 31, 2023 | -3.213M |
| September 30, 2023 | -9.107M |
| June 30, 2023 | -13.62M |
| March 31, 2023 | 3.013M |
| December 31, 2022 | -17.16M |
| September 30, 2022 | 14.98M |
| June 30, 2022 | -13.12M |
| March 31, 2022 | -18.28M |
| December 31, 2021 | -16.80M |
| September 30, 2021 | -18.08M |
| June 30, 2021 | 10.71M |
| March 31, 2021 | -18.29M |
| December 31, 2020 | -21.63M |
| September 30, 2020 | -17.63M |
| June 30, 2020 | -18.31M |
| March 31, 2020 | -14.54M |
| December 31, 2019 | -14.02M |
| September 30, 2019 | 3.039M |
| June 30, 2019 | -13.55M |
| Date | Value |
|---|---|
| March 31, 2019 | -16.56M |
| December 31, 2018 | -12.34M |
| September 30, 2018 | -13.62M |
| June 30, 2018 | -16.31M |
| March 31, 2018 | -16.75M |
| December 31, 2017 | -13.43M |
| September 30, 2017 | -12.26M |
| June 30, 2017 | -16.64M |
| March 31, 2017 | -13.40M |
| December 31, 2016 | -14.39M |
| September 30, 2016 | -12.23M |
| June 30, 2016 | -11.76M |
| March 31, 2016 | -9.789M |
| December 31, 2015 | -9.868M |
| September 30, 2015 | -9.174M |
| June 30, 2015 | -6.414M |
| March 31, 2015 | -6.737M |
| December 31, 2014 | -4.649M |
| September 30, 2014 | -3.319M |
| June 30, 2014 | -3.219M |
| March 31, 2014 | -0.707M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-91.21M
Minimum
Jun 2024
14.98M
Maximum
Sep 2022
-15.13M
Average
-15.26M
Median
Net Income (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 106.08M |
| Arbutus Biopharma Corp | -19.72M |
| GlycoMimetics Inc | -9.824M |
| FibroGen Inc | -17.08M |
| Cue Biopharma Inc | -8.66M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 17.39M |
| EPS Diluted (Quarterly) | -2.45 |
| Enterprise Value | -4.423M |
| Earnings Yield | -131.4% |
| Normalized Earnings Yield | -33.53 |